Jardiance Vs. Mounjaro: Drug Comparison

Jardiance^® (empagliflozin) is an oral medication used to improve blood sugar control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, as an adjunct to diet and exercise. It is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Additionally, Jardiance helps reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. It is also used to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. This medication works as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promoting the excretion of glucose through the urine​.

Mounjaro^® (tirzepatide) is an injectable medication used to treat type 2 diabetes by improving blood sugar control and promoting weight loss. It functions by activating two receptors, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance insulin secretion and slow gastric emptying. Mounjaro is administered once weekly, with dose adjustments made based on the patient's response. Common side effects include nausea, diarrhea, and decreased appetite. It should be used with caution in individuals with a history of thyroid cancer or multiple endocrine neoplasia syndrome type 2​.

Sodium-glucose co-transporter 2 (SGLT2) inhibitor

Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist

Jardiance (empagliflozin) is indicated:

• To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure

• To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression

• To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease

• As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus

Mounjaro (tirzepatide) is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

• Typically taken orally once daily

• Comes in 10 mg and 25 mg tablets

• Typically taken as an injection once weekly

• Comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose pens or single-dose vials

Most common adverse reactions (5% or greater incidence) were:

• Urinary tract infections

• Female genital fungal infections

The most common adverse reactions, reported in ≥5% of patients treated with Mounjaro are:

• Nausea

• Diarrhea

• Decreased appetite

• Vomiting

• Constipation

• Indigestion

• Abdominal pain

• Hypersensitivity to empagliflozin or any of the excipients in Jardiance

• See the Full Prescribing Information for information on drug interactions and interference of Jardiance with laboratory tests

• Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2

• Known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro

• Drug interactions: Mounjaro delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications

• Diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis

• Volume depletion

• Urosepsis and pyelonephritis

• Low blood sugar

• Necrotizing fasciitis of the perineum (Fournier's gangrene)

• Genital fungal infections

• Lower limb amputation

• Hypersensitivity reactions

• Pregnancy: Potential risk to a fetus especially during the second and third trimesters

• Breastfeeding: Not recommended when breastfeeding

• Pancreatitis

• Low blood sugar with concomitant use of insulin secretagogues or insulin

• Hypersensitivity reactions

• Acute kidney injury

• Severe gastrointestinal disease

• Diabetic retinopathy complications in patients with a history of diabetic retinopathy

• Acute gallbladder disease

• Pregnancy: Based on animal study, may cause fetal harm

• Females of reproductive potential: Females using oral contraceptives should consider switching to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation

WARNING: RISK OF THYROID C-CELL TUMORS

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

*This information is from the label for brand name Jardiance^®. See the Full Prescribing Information for more complete information.

*This information is from the label for brand name Mounjaro. See the Full Prescribing Information for more complete information. Tirzepatide, the active ingredient in Mounjaro, may also be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient tirzepatide.